Stockreport

ESMO 2024: BMS cuts ties as Immatics regains full rights to bispecific [Yahoo! Finance]

Immatics N.V. - Ordinary Shares  (IMTX) 
PDF BMS has handed back both the development and commercialisation rights for IMA401 to the biopharmaceutical company after a $150m upfront payment in 2021, with an expecte [Read more]